An Era of Biological Treatment in Systemic Lupus Erythematosus

Overview

Journal Clin Rheumatol

Publisher Springer

Specialty Rheumatology

Date 2017 Dec 14

PMID 29234909

Citations 3

Authors

Jing He

Zhanguo Li

Affiliations

Soon will be listed here.

Citing Articles

What are the benefits and harms of belimumab for patients with systemic lupus erythematosus?: A Cochrane Review summary with commentary.

Iolascon G Int J Rheum Dis. 2021; 24(10):1331-1333.

PMID: 34523249 PMC: 9292524. DOI: 10.1111/1756-185X.14214.

The new complement inhibitor CRIg/FH ameliorates lupus nephritis in lupus-prone MRL/lpr mice.

Shi Y, Yao W, Sun L, Li G, Liu H, Ding P BMC Nephrol. 2019; 20(1):424.

PMID: 31752725 PMC: 6873683. DOI: 10.1186/s12882-019-1599-0.

Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial.

He J, Zhang R, Shao M, Zhao X, Miao M, Chen J Ann Rheum Dis. 2019; 79(1):141-149.

PMID: 31537547 PMC: 6937406. DOI: 10.1136/annrheumdis-2019-215396.

References

Petri M, Wallace D, Spindler A, Chindalore V, Kalunian K, Mysler E . Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study. Arthritis Rheum. 2013; 65(4):1011-21. PMC: 3654174. DOI: 10.1002/art.37824. View

Yang J, Chu Y, Yang X, Gao D, Zhu L, Yang X . Th17 and natural Treg cell population dynamics in systemic lupus erythematosus. Arthritis Rheum. 2009; 60(5):1472-83. DOI: 10.1002/art.24499. View

Clowse M, Wallace D, Furie R, Petri M, Pike M, Leszczynski P . Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials. Arthritis Rheumatol. 2016; 69(2):362-375. PMC: 5299488. DOI: 10.1002/art.39856. View

Doria A, Iaccarino L, Ghirardello A, Zampieri S, Arienti S, Sarzi-Puttini P . Long-term prognosis and causes of death in systemic lupus erythematosus. Am J Med. 2006; 119(8):700-6. DOI: 10.1016/j.amjmed.2005.11.034. View

Finck B, Linsley P, Wofsy D . Treatment of murine lupus with CTLA4Ig. Science. 1994; 265(5176):1225-7. DOI: 10.1126/science.7520604. View

Diaz-Lagares C, Croca S, Sangle S, Vital E, Catapano F, Martinez-Berriotxoa A . Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. Autoimmun Rev. 2011; 11(5):357-64. DOI: 10.1016/j.autrev.2011.10.009. View

Liao W, Lin J, Leonard W . Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity. 2013; 38(1):13-25. PMC: 3610532. DOI: 10.1016/j.immuni.2013.01.004. View

Navarra S, Guzman R, Gallacher A, Hall S, Levy R, Jimenez R . Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011; 377(9767):721-31. DOI: 10.1016/S0140-6736(10)61354-2. View

Wang D, Niu L, Feng X, Yuan X, Zhao S, Zhang H . Long-term safety of umbilical cord mesenchymal stem cells transplantation for systemic lupus erythematosus: a 6-year follow-up study. Clin Exp Med. 2016; 17(3):333-340. DOI: 10.1007/s10238-016-0427-0. View

10.

Suntharalingam G, Perry M, Ward S, Brett S, Castello-Cortes A, Brunner M . Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. 2006; 355(10):1018-28. DOI: 10.1056/NEJMoa063842. View

11.

Furie R, Nicholls K, Cheng T, Houssiau F, Burgos-Vargas R, Chen S . Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study. Arthritis Rheumatol. 2014; 66(2):379-89. DOI: 10.1002/art.38260. View

12.

Bennett L, Palucka A, Arce E, Cantrell V, Borvak J, Banchereau J . Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med. 2003; 197(6):711-23. PMC: 2193846. DOI: 10.1084/jem.20021553. View

13.

Lu T, Ng K, Cambridge G, Leandro M, Edwards J, Ehrenstein M . A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum. 2009; 61(4):482-7. DOI: 10.1002/art.24341. View

14.

Wilhelm T, Magder L, Petri M . Remission in systemic lupus erythematosus: durable remission is rare. Ann Rheum Dis. 2016; 76(3):547-553. DOI: 10.1136/annrheumdis-2016-209489. View

15.

Pozsgay J, Szekanecz Z, Sarmay G . Antigen-specific immunotherapies in rheumatic diseases. Nat Rev Rheumatol. 2017; 13(9):525-537. DOI: 10.1038/nrrheum.2017.107. View

16.

Merrill J, Neuwelt C, Wallace D, Shanahan J, Latinis K, Oates J . Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2009; 62(1):222-33. PMC: 4548300. DOI: 10.1002/art.27233. View

17.

He J, Tsai L, Leong Y, Hu X, Ma C, Chevalier N . Circulating precursor CCR7(lo)PD-1(hi) CXCR5⁺ CD4⁺ T cells indicate Tfh cell activity and promote antibody responses upon antigen reexposure. Immunity. 2013; 39(4):770-81. DOI: 10.1016/j.immuni.2013.09.007. View

18.

Li Z, Mu R, Dai Z, Gao X . T cell vaccination in systemic lupus erythematosus with autologous activated T cells. Lupus. 2005; 14(11):884-9. DOI: 10.1191/0961203305lu2239oa. View

19.

Kaul A, Gordon C, Crow M, Touma Z, Urowitz M, van Vollenhoven R . Systemic lupus erythematosus. Nat Rev Dis Primers. 2016; 2:16039. DOI: 10.1038/nrdp.2016.39. View

20.

Rovin B, Furie R, Latinis K, Looney R, Fervenza F, Sanchez-Guerrero J . Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012; 64(4):1215-26. DOI: 10.1002/art.34359. View